Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/20/18
End: 10/18/23
Due: 10/18/24
Phase: N/A
Priority: Normal
Start: 07/31/08
End: 10/31/09
Due: 10/31/10
Phase: N/A
Priority: Normal
Start: 11/05/21
End: 04/20/22
Due: 04/20/23
Phase: N/A
Priority: Normal
Start: 10/26/21
End: 06/30/27
Due: 06/30/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | NCT03255070 | Ambrx, Inc. | user2@example.com | None | 2018-03-20 | 2023-10-18 | 2024-10-18 | - | - | 2025-07-14 |
| Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD). | NCT00778518 | Ambrx, Inc. | user2@example.com | None | 2008-07-31 | 2009-10-31 | 2010-10-31 | - | - | 2025-07-14 |
| ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | NCT05041972 | Ambrx, Inc. | user2@example.com | None | 2021-11-05 | 2022-04-20 | 2023-04-20 | - | - | 2025-07-14 |
| ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | NCT04829604 | Ambrx, Inc. | user2@example.com | None | 2021-10-26 | 2027-06-30 | 2028-06-30 | - | - | 2025-07-14 |